These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 8879607

  • 1. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA, Marshall GM, Giri N, Vowels MR, Russell SJ.
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
    Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S.
    Bone Marrow Transplant; 2003 Sep; 32(6):543-8. PubMed ID: 12953124
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
    Moussalem M, Esperou Bourdeau H, Devergie A, Baruchel A, Ribaud P, Socie G, Parquet N, Traineau R, Hirsch I, Schaison G.
    Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
    von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, Demeocq F, Mechinaud-Lacroix F, Michel G, Sadoun A, Bernaudin F, Cornu G, Donadieu J.
    Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
    [Abstract] [Full Text] [Related]

  • 5. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
    Kato K, Yoshida N, Matsumoto K, Matsuyama T.
    Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I, Klein JL, Kapoor N, Harman GS, Avalos BR.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T, Kojima S, Kato K.
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma.
    Yoshihara T, Naya M, Tsunamoto K, Hojo M, Hibi S, Morimoto A, Todo S, Imashuku S.
    Anticancer Res; 2003 Jul; 23(2C):1739-42. PubMed ID: 12820450
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N.
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [Abstract] [Full Text] [Related]

  • 14. The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia.
    Wang C, Qiao Z, Yang L, Ma L, Zhang H, Zhang J.
    Chin Med J (Engl); 1996 Apr; 109(4):304-7. PubMed ID: 8758293
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan).
    Deconinck E, Cahn JY, Milpied N, Jouet JP, Vernant JP, Esperou H, Lioure B, Bordigoni P, Leblond V, Troussard X, Caillot D, Cordonnier JM, Hervé P.
    Bone Marrow Transplant; 1997 Nov; 20(9):731-5. PubMed ID: 9384474
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
    Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
    [Abstract] [Full Text] [Related]

  • 17. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Wachowiak J, Bettoni C, Lange A, Malicki J, Kaczmarek-Kanold M, Głuszak B, Suchnicki K, Daszkiewicz P, Ebell W.
    Acta Haematol Pol; 1995 Jan; 26(4):377-84. PubMed ID: 8571739
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.